End-to-end specialist AI to support high quality patient care 

New York, December 16 2025: Horizon Health Network (Horizon), the operator of 12 hospitals and more than 100 medical facilities and clinics across the province of New Brunswick in Canada, has entered into a partnership with global health innovator Qure.ai to evaluate and implement an end-to-end artificial intelligence (AI) lung cancer care suite.

This agreement supports Horizon's preparation for an anticipated province-wide low-dose CT lung cancer screening program for high-risk patients. The collaboration also enables proactive advancement in chest X-ray incidental lung cancer detection across a broader patient population.

Through this innovative partnership, Horizon is building the infrastructure, workflows, and clinical integration capabilities to be ready for coordinated provincial lung cancer screening initiatives.

Lung cancer is the leading cause of cancer death in North America, accounting for more cancer deaths than colon, breast, and prostate cancers combined. Early detection at stage I, rather than late stage III or IV, boosts survival rates and reduces the need for therapeutic or surgical intervention. 

“This agreement with Qure.ai reflects our commitment to innovation and advancing patient care through rigorous evaluation of emerging technologies," states Zach Kilburn, Chief Digital Officer at Horizon Health Network. "The AI-powered software will integrate seamlessly with our existing infrastructure to support clinical confidence in decision-making and streamline patient management workflows. By building this infrastructure now, we're positioning our clinicians to support high-quality, coordinated lung cancer care across the health care ecosystem.”

“Proactive CT-based lung cancer screening strategies are a giant step forward, but only one part of the battle against lung cancer. AI has the power to cast a wider net, to identify small lung nodules that can be indicative of early-stage lung cancer on routine CT and X-rays that may be obtained for other indications. This can include pre-operative examinations or trauma related admissions,” states Jim Mercadante, Chief Commercial Officer at Qure.ai. “We are delighted to be entering into a progressive lung cancer AI partnership with Horizon Health Network in Canada and supporting them with digital transformation.” 

Qure.ai is a global leader in healthcare AI and digital health boasting deployments in over 107 countries across 5200+ sites. The Qure.ai lung cancer solutions have class III medical device license approval from Health Canada and FDA clearance in the USA*. They can be deployed as individual products, or collectively as a suite for a unified and cohesive workflow. qXR-LN powers the incidental detection of lung nodules on chest X-ray; qCT-Quant assesses and quantifies lung nodules on CT scans; and qTrack coordinates patient management to support lung nodule clinics or nurse navigators.  

Notes to editors:

* Regulatory clearances of AI algorithms vary by region 

About Qure.ai   

Qure.ai is a global health tech company that innovates AI-enabled healthcare solutions to drive early clinical diagnosis and boost seamless patient care coordination. Qure's solutions power the efficient identification and management of Tuberculosis (TB), Lung Cancer and Neurocritical findings to support clinicians and propel developments in the pharmaceutical and medical device industries. The company empowers healthcare workers or health systems by helping to identify conditions fast, prioritize treatment planning and ultimately improve quality of patient life. 

Qure.ai has deployments in over 100 countries, with regional offices in New York, London, Dubai and Mumbai. It is a TIME100 Most Influential Company 2025.  

For media queries:

Georgina Wright - Georgina.wright@qure.ai